KMPR heads into the post-earnings week with short sellers quietly trimming and the stock giving back some of its recent gains.
The price action tells a cautious story. KMPR closed at $32.88 on Tuesday, down 2% on the day and off about 2.2% for the week. That follows a 7.4% rally over the prior month — so the latest pullback looks more like digestion than a reversal. The company reported Q1 2026 results on May 6, and without yet-available price-reaction data for that event, the trading context is essentially: a stock that clawed back ground in April, now facing near-term pressure.
The borrow market is relaxed — this is not a short-squeeze setup. Short interest runs at 5.4% of the free float, roughly 3.17 million shares. That figure ticked down 5% on Tuesday alone and has barely moved over the past week, suggesting shorts are not piling in post-earnings. The official FINRA settlement data from mid-April shows a slightly higher 3.33 million shares short, with days-to-cover near five — meaningful, but not alarming. Availability is high and borrow remains cheap at 0.40% annually, having eased about 4.5% over the week. The lending market offers no tension here.
Options positioning sits right in line with recent history, which itself is notably cautious. The put/call ratio runs at 3.60 — well above a "normal" reading for most stocks — but this is close to KMPR's own 20-day average of 3.54. In other words, the option market has been consistently defensively skewed for weeks. The z-score is essentially flat at 0.10. The 52-week high on the PCR hit 10.07, meaning the current elevated reading is nowhere near the extremes this market has seen. Hedging is baked in; there's no fresh escalation.
The analyst picture has soured meaningfully over the past year. UBS — the most recent move of note, on April 8 — cut its target from $56 to $48 while holding a Buy rating. That single action captures the broader theme: the Street still sees upside from here (the mean target of ~$54.67 implies about 66% above the current price), but confidence has eroded. Citizens downgraded in February, and William Blair moved to Underperform in December. Piper Sandler has cut its target three times in the past twelve months and sits at Underweight. The trajectory is one of successive markdown, not re-rating. The PE multiple is a modest 7.7x with a P/B below 0.66 — value-screen territory, but the low multiples reflect genuine underwriting concerns, not overlooked quality. The EV/EBIT factor score ranks only in the 19th percentile across the universe, a signal the market is not yet convinced the profit engine is fixed.
The institutional holder base adds an interesting wrinkle. BlackRock added over 3.5 million shares in the quarter to April 30, pushing its stake to 11.4% — a notably large addition. State Street added 530,000 shares over the same period, and Northern Trust added 211,000. These are largely passive flows tracking index rebalances, but the scale of BlackRock's move stands out as worth monitoring. The last insider transactions on record are from early February, when a cluster of executives — including the acting CFO and CIO — sold small parcels near $34.24. The values were token-sized (under $35,000 each) and likely represent routine share-plan disposals rather than a bearish signal.
The nearest earnings parallel worth flagging comes from February 5, when the stock fell 11% on the day following Q4 2025 results and slid 15.9% over the following week. Whether Q1 2026 triggers a comparable reaction is the central question to watch now that results are on the tape.
See the live data behind this article on ORTEX.
Open KMPR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
